跳至主要内容
临床试验/NCT02884154
NCT02884154已完成不适用

Feasibility and Yield of a New 20 G ProCore Needle With Coiled Sheath in the Gastrointestinal Subepithelial Tumors

Pusan National University Hospital0 个研究点目标入组 39 人开始时间: 2016年8月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
39
主要终点
diagnostic sufficiency

研究概览

简要总结

The exact incidence of subepithelial tumors (SETs) in the gastrointestinal (GI) tract is unknown, but the prevalence of gastric SETs detected during routine esophagogastroduodenoscopy is 0.36%. GI SETs may include leiomyoma, GI stromal tumor (GIST), schwannoma, lipoma, cyst, or ectopic pancreas. Surgical resection is the principal diagnostic and therapeutic method for SETs, especially for large and symptomatic ones. Preoperative pathological diagnosis of SETs may facilitate clinical decision making, but conventional endoscopic forceps biopsy does not yield adequate amounts of subepithelial tissue for definitive diagnosis.

Although endoscopic ultrasonography (EUS) is the best imaging modality for the evaluation of SETs, it cannot substitute histopathological diagnosis. EUS-guided fine-needle aspiration (EUS-FNA) may provide adequate amounts of tissue for the diagnosis of SETs, but it does not always afford adequate samples for immunohistochemical analysis because of the often small number of cells obtained by aspiration. Since some SETs, especially GI mesenchymal tumors such as GIST or schwannoma, have varied morphologic appearances, and diagnosis using a small biopsy is not straightforward, immunohistochemical analysis is strongly advisable, if not essential. EUS-guided Trucut biopsy (EUS-TNB) may overcome the limitations of EUS-FNA in procuring sufficient core tissue specimens. Although EUS-TNB is more accurate than EUS-FNA for diagnosing GI mesenchymal tumors, the rigidity of its 19-gauge (G) caliber and the mechanical friction of the firing mechanism produced by the torqued echoendoscope limit its use for SETs located in the gastric antrum and duodenum. Therefore, a needle facilitating adequate histological core sampling with easy maneuverability needs to be established. A 19G EUS-guided fine-needle biopsy (EUS-FNB) device with ProCore reverse-bevel technology was recently introduced. A multicenter study revealed that histological samples could be successfully obtained using this needle in most patients having GI SETs, with a diagnostic accuracy of >80%.10 However, because of technical difficulties with this needle in the gastric antrum and duodenum, the same FNB device was recently developed in a 20 G platform with coiled sheath. This prospective, multicenter study aimed to evaluate feasibility, yield, and diagnostic accuracy of a newly developed 20 G ProCore needle with coiled sheath in patients with GI SETs.

详细描述

Patients and Methods

Patients with newly diagnosed GI SETs will be prospectively enrolled at 8 university hospitals in Korea between May and December 2016, if they met the following criteria: having a hypoechoic mass in the submucosal and/or proper muscle layers on the basis of EUS and tumor >2 cm in size. Exclusion criteria are: SETs were not located in the submucosal and/or proper muscle layers on EUS; EUS revealed the characteristic findings of lipoma, cyst, vessel or extraluminal lesions; the platelet count was <50,000/mm3 and prothrombin time was <50%; or the patient did not provide consent to undergo the study. This study is approved by the Institutional Review Board of each hospital and conducted in accordance with the Declaration of Helsinki and its amendments and the Good Clinical Practice guidelines. All enrolled patients provide written informed consents to participate in the study.

Technique for EUS-FNB

All procedures are performed by using a linear array echoendoscope (Olympus UCT-140, UCT-240; Olympus, Tokyo, Japan or PentaxEG-3870UTK; Pentax, Tokyo, Japan) with the patients placed in the left lateral decubitus position under conscious sedation.

Before the study commenced, all participating endosonographers discuss the procedural steps in detail. Technical details of the standard tissue-acquisition protocol are as follows. After the target lesion is endosonographically visualized and the region scanned for SETs using color or pulsed Doppler, FNB is performed at the esophagus, stomach, duodenum or rectum, depending on the lesion location. The needle is advanced into the target tissue under endosonographic guidance.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

性别
All
接受健康志愿者
否

入选标准

  • •Having a hypoechoic mass in the submucosal and/or proper muscle layers on the basis of EUS and tumor >2 cm in size

排除标准

  • •SETs were not located in the submucosal and/or proper muscle layers on EUS
  • •EUS revealed the characteristic findings of lipoma, cyst, vessel or extraluminal lesions; the platelet count was <50,000/mm3 and prothrombin time was <50%
  • •The patient did not provide consent to undergo the study

研究组 & 干预措施

Arm who will undergo EUS-FNB

Other

干预措施: Echotip ProCoreⓇ HD Ultrasound Biopsy Needle (Device)

结局指标

主要结局

diagnostic sufficiency

时间窗: up to 2 weeks

Diagnostic sufficiency is defined as the proportion of patients in whom the histopathological diagnosis could be established within three needle passes.

次要结局

  • complications(up to 4 weeks)
  • diagnostic failure rate(up to 2 weeks)
  • technical failure rate(up to 1 day)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Gwang Ha Kim

Principal Investigator

Pusan National University Hospital

相似试验